Key facts
- MetalloBio’s last known valuation is $5.3M (Mar 2025).
- It has raised $950K.
- Notable investors include Innovate UK, SFC Capital, UK Research and Innovation, Engineering and Physical Sciences Research Council, Enterprise Hub - Royal Academy of Engineering — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for MetalloBio
- ·The full record, as it builds
Funding rounds
No funding rounds for MetalloBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MetalloBio
Developer of novel antimicrobial compounds designed to treat complicated infections caused by multidrug-resistant pathogenic bacteria. The company offers systemically delivered antibiotic drugs with new mechanisms of action and antimicrobial agents embedded in proprietary coatings for medical devices, enabling healthcare providers and manufacturers of urinary catheters and coated products to combat resistant infections without cross-reaction to existing antibiotics.
- Sector
- Healthcare
- HQ
- Sheffield, United Kingdom
- Founded
- 2021
- Employees
- 8
- Website
- metallobio.com/
- Ownership
- Privately Held (backing)
MetalloBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MetalloBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MetalloBio in its N-PORT filings yet. We sweep new filings monthly.